Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights Nov 14, 2017
Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights Nov 09, 2017
Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights Nov 09, 2017
Fortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain Injury Nov 08, 2017
Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting Nov 01, 2017
Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting Nov 01, 2017
Fortress Biotech Announces Subsidiary Data to Be Presented at 59th American Society of Hematology Annual Meeting Nov 01, 2017
Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain Oct 31, 2017
